Tags: Biomarkers
- addf access
- aducanumab
- agenebio
- alzecure foundation
- amylyx
- amyotrophic lateral sclerosis
- amyvid™
- apoe
- asceneuron
- axxam
- batten disease
- benefit
- beta-amyloid
- bill gates
- biogen
- biomarkers
- birax
- blog
- caregiving
- cerebrospinal fluid csf
- chronic traumatic encephalopathy cte
- clinical trials
- cognitive vitality
- cohbar
- combination therapy
- comparative effectiveness
- concussions
- conference
- connoisseur's dinner
- cypralis
- diagnostics accelerator
- drug discovery
- early-onset alzheimer's
- epigenetics
- fall luncheon
- frontotemporal dementia
- genetics
- giving tuesday
- gliacure
- great ladies luncheon
- harrington discovery institute
- hope on the horizon
- inflammation
- klogene therapeutics
- lewy body dementia
- ltd.
- m3 biotechnology
- medicare
- melvin r. goodes prize
- memories matter
- mild cognitive impairment
- misfolded proteins
- mitochondria & metabolic function
- mri
- multiple scleroris
- neuroimaging
- neurolucent
- neuroprotection
- neurotherapia
- neurotransmitters
- new staff
- new trustees
- nyc marathon
- oryzon genomics
- partnership
- pet scan
- pharmatrophix
- policy
- prevention
- prion disease
- proteostasis
- psychogenics
- repurposing
- rexceptor
- rodin therapeutics
- runners for alzheimer's research
- supplements
- tau
- tdp-43
- tetra discovery partners
- traumatic brain injury
- vascular
- vascular dementia
- venture philanthropy
- vivreon biosciences
- world alzheimer's day
- year in review
blog
December 10, 2019
Stepping Forward in Alzheimer’s Disease Research: A Combination Therapy Approach
Chief Medical Officer at Amylyx Pharmaceuticals gives a closer look at how far they have come in their recently expanded phase 2 clinical trial, supported in part by the ADDF, which is studying a combination approach to treating people with Alzheimer’s disease.
announcements
November 22, 2019
Major Research Funding for Blood Test to Accelerate Clinical Trials for New Frontotemporal Degenerat
The Bluefield Project to Cure FTD Receives $1.2 Million Award from the Alzheimer’s Drug Discovery Foundation’s Diagnostics Accelerator
announcements
October 17, 2019
Alzheimer’s Drug Discovery Foundation Partners with Shionogi and Janssen Pharmaceuticals for its Dia
The Alzheimer’s Drug Discovery Foundation (ADDF) announced a partnership with Shionogi & Co., Ltd. and Janssen Pharmaceuticals, Inc. as part of its Diagnostics Accelerator, an initiative that aims to fast-track the development of novel biomarkers for the early detection of Alzheimer's disease and related dementias.
announcements
October 15, 2019
$3.2 Million in New Funding Focused on Biomarkers and Moving Toward New Therapies
These recent investments reflect the ADDF's commitment to advancing tools for early detection, with an emphasis on exploring the different pathologies associated with aging.
announcements
May 30, 2019
Alzheimer’s Drug Discovery Foundation Announces the First Diagnostics Accelerator Award Recipients
The first four awards from the first request for proposals total up to approximately $3.5 million.
announcements
May 10, 2019
$7.1 Million in New Funding Illustrates the ADDF’s Strong Support of a Diverse Pipeline
The ADDF announces $7.1 million in new investments, which reflect our strategy to advance drug discovery and clinical trials, including the development of biomarkers and prevention methods.
announcements
April 2, 2019
The ADDF Announces New Research Initiative to Advance Digital Tools for Detection for Alzheimer’s
The ADDF's Diagnostics Accelerator is seeking to fund the development of digital tools to capture quantifiable biomarkers.
announcements
March 21, 2019
ADDF Statement on Biogen and Eisai Discontinuing Trials of Aducanumab
Pharmaceuticals company Biogen and its partner Eisai announced that they will cease clinical trials for aducanumab after it was indicated the trials were unlikely to succeed.
blog
January 14, 2019
Top 5 Advances in 2018
In 2018 we have seen increased investments in Alzheimer's biomarkers and increased interest in prevention.
blog
November 13, 2018
Leading Scientists Share Exciting Research Developments at the ADDF Fall Symposium
At the ADDF's Ninth Annual Fall Symposium, Richard S. Isaacson, Michelle M. Mielke, and Mark A. Mintun discussed Alzheimer's biomarkers and prevention.
blog
September 24, 2018
Two Decades of Research: The ADDF’s 19th International Conference on Alzheimer’s Drug Discovery
Researchers shared updates on their approaches to developing Alzheimer's treatments at our annual conference.
announcements
September 21, 2018
19th International Conference on Alzheimer’s Drug Discovery Highlights Multiple Approaches
The conference, organized by the Alzheimer's Drug Discovery Foundation, focused on gene therapy and alternative modalities for neurodegenerative diseases, progress in developing novel drugs, as well as the need for new biomarkers.
announcements
September 13, 2018
$2.3 Million in New Funding Focused on Novel Biomarkers and Treatments
The Alzheimer's Drug Discovery Foundation (ADDF) announces funding for a novel biomarker and two Phase I clinical studies.
blog
August 2, 2018
Top Five Highlights from AAIC 2018
The ADDF looks back at the 2018 Alzheimer's Association International Conference.
announcements
July 17, 2018
New Coalition of Philanthropists Including Bill Gates, Leonard Lauder Commit More Than $30 Million
Bill Gates and Leonard Lauder have announced Diagnostics Accelerator, an initiative to develop new biomarkers for early detection for Alzheimer's.
announcements
May 10, 2018
$2.5 Million in New Funding Exemplifies ADDF’s Strategy
We announce $2.5 million in new funding, which reflects the comprehensive nature of our strategy to prevent and treat Alzheimer’s disease.
announcements
May 1, 2018
Partnership with FNIH Will Drive New Biomarkers for Alzheimer’s
The ADDF has joined an initiative from the Foundation for the National Institutes of Health (FNIH) Biomarkers Consortium that will improve diagnosis and the development of targeted therapies for Alzheimer's disease.
blog
January 30, 2018
Meeting the Challenge of CTE
For CTE Awareness Day, we highlight our support of diagnostic tools and treatments for this disease.
blog
January 2, 2018
Top Five Alzheimer’s Advances in 2017
Our top five advances in 2017 spotlight the substantial progress we have made toward conquering Alzheimer’s and other neurodegenerative diseases.
blog
December 28, 2017
Alzheimer’s Biomarkers, Explained
Learn what a biomarker is, why they matter to the ADDF, which biomarkers we have, and which ones we need.
announcements
November 14, 2017
Three New Grants Keep Promising Programs Forging Ahead
The Alzheimer’s Drug Discovery Foundation (ADDF) announces three new investments, all of which are for programs that the ADDF previously funded.
announcements
September 13, 2017
18th Annual Conference on Alzheimer’s Drug Discovery Showcases Non-Amyloid Research
Nearly 200 academic and industry researchers came together to share updates on innovative preclinical and clinical-stage Alzheimer’s disease research at the 18th Annual Conference on Alzheimer's Drug Discovery.
announcements
September 5, 2017
New Funding Supports Blood Test for Early Alzheimer’s
The ADDF announces two new grants, including support for a blood test designed to detect Alzheimer’s disease in early stages of development and a gene therapy for frontotemporal dementia.
announcements
July 11, 2017
Latest Funding Includes Support for Innovative Clinical Trial
The ADDF announces four new grants, including support for an innovative clinical trial, two novel drug programs, and a biomarker for CTE.
blog
January 10, 2017
Top Five Alzheimer’s Advances in 2016
In 2016, we made great progress toward finding drugs to prevent and treat Alzheimer’s, as our top five advances demonstrate.
Alzheimer's Drug Discovery Foundation
A GuideStar-Rated Charity
New York, NY 10019
info@alzdiscovery.org
212.901.8000
© Copyright 2024. The Alzheimer's Drug Discovery Foundation, a not-for-profit, section 501 (c)(3).